Preclinical study in multiple myeloma models revealed that FT suppressed the STAT3/5-DNA binding capacity while simultaneously inhibiting the activation of upstream kinases JAK1, JAK2 and Src [37]. The gene discussed is SRC; the disease is plasma cell myeloma.